Novartis India slumped 12.06% to Rs 728 at 12:30 IST on BSE after the company's buyback plan disappointed investors. The company announced its buyback plan after market hours yesterday, 26 May 2016. Meanwhile, the S&P BSE Sensex was up 181.32 ... Capital Market, 2 days ago
Novartis India shares jump over 17% on buyback plan - Economic Times, 4 days ago
Novartis India surges as company mulls share buyback plan - Economic Times, 5 days ago
Drugmaker Novartis said on Thursday its board of directors has unanimously approved a buyback proposal for the purchase of the company's shares at ₹760 per share. The company's shares on the BSE closed on Thursday at ₹827, after the stock had ...Hindu Business Line, 2 days ago Novartis to consider buyback at Thursday board meet Business Line, 4 days ago
Novartis India, which sells the oncology drug Glivec, said on Thursday it will buy back shares worth Rs 290 crore. In a stock exchange filing, the pharmaceutical company said it would acquire close to 38 lakh shares at a price of Rs 760 a share. The ...Financial Express, 2 days ago
Novartis' CEO Says Company Open To Selling Its $14 Billion Stake In Roche 'If The Opportunity Were Right'
Switzerland-based Novartis AG (ADR) (NYSE: NVS ) owns a roughly $14 billion stake in rival Roche Holding Ltd. (ADR) (OTC: RHHBY ) and is actively shopping for buyers to acquire its stake. According to Reuters, Novartis has been working with ...Benzinga.com, 3 days ago Novartis willing to sell Roche stake without demanding premium - CEO 4 Traders, 4 days ago
Seqirus receives FDA approval for FLUCELVAX QUADRIVALENT (Influenza Vaccine) for people four years of age and older
the CSL Group and its Affiliates acquired the influenza vaccines business of Novartis AG in the US. The influenza vaccines business, previously owned by Novartis, has been integrated into CSL's influenza vaccine business and now operates as Seqirus.Benzinga.com, 5 days ago FLUAD(TM) (influenza vaccine, adjuvanted) to Help Protect Elderly Patients Against Influenza Pharmacy Times, 5 days ago 5/24/16 - Seqirus receives FDA approval for FLUCELVAX QUADRIVALENT?¢ (Influenza Vaccine) for people four years of age and older Pharmacy Choice, 5 days ago
Email this Print Novartis India has surged 15% to Rs 818 on the BSE in early morning trade after the pharmaceutical company announced that its board will meet on Thursday, May 26, 2016, to consider a proposal for buyback of the company's equity ...Smart Investor, 5 days ago
Troikaa pharmaceutical alleged that the approval for manufacturing and marketing of the injection is arbitrary in view of safety concerns over Transcutol New Delhi: The Delhi high court on Friday sought a response from the centre, Novartis India and ...Livemint.com, 1 week ago
Novartis is putting its utmost efforts into eradicating the sluggish acceptance pattern of the drug in the medical community Novartis AG (ADR) ( NYSE:NVS ) is working diligently to bring back heart failure drug Entresto, after the drug's ...Bidness Etc, 1 week ago
Novartis AG (ADR) (NYSE: NVS ) announced on Thursday the establishment of FortiHFy, short for Forti fying H eart F ailure clinical evidence and patient qualit y of life. FortiHFy is an umbrella clinical program that consists of over 40 active or ...Benzinga.com, 1 week ago
Novartis head of pharmaceuticals to leave the company as his role gets split into two Novartis AG (ADR) ( NYSE:NVS ) announced on Tuesday the departure of its head of pharmaceuticals, David Epstein, as the company restructures its business ...Bidness Etc, 1 week ago Novartis Splits Up Drug Unit as Top Executive Will Depart Bloomberg, 1 week ago Novartis AG's Pharma Head Exits as Drug Business is Split into Two BioSpace, 1 week ago Novartis Says Drug-Unit Chief To Leave Firm -- WSJ 4 Traders, 1 week ago
More from: , Morningstar.com...and 6 other sources
on your WebpageAdd Widget >Get your members hooked!